Get the Stockscreener App
4.01
1.26%
0.05
After Hours:
3.93
-0.08
-2.00%
Cytek Biosciences Inc stock is traded at $4.01, with a volume of 853.52K.
It is up +1.26% in the last 24 hours and down -13.76% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$3.96
Open:
$3.96
24h Volume:
853.52K
Relative Volume:
1.08
Market Cap:
$517.86M
Revenue:
$201.49M
Net Income/Loss:
$-66.54M
P/E Ratio:
-7.716
EPS:
-0.5197
Net Cash Flow:
$-8.88M
1W Performance:
+17.77%
1M Performance:
-13.76%
6M Performance:
-31.80%
1Y Performance:
+63.67%
1-Day Range:
$3.94
$4.06
1-Week Range:
$3.34
$4.06
52-Week Range:
$2.37
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.01 | 511.40M | 201.49M | -66.54M | -8.88M | -0.5197 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $4.12 - Moomoo
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives - Sahm
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures - TipRanks
Cytek Biosciences Q1 Revenue Increases to $44.1 Million - HarianBasis.co
Cytek (CTKB) Q1 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences, Inc.Common Stock (Nasdaq:CTKB) Stock Quote - FinancialContent
Cytek Biosciences Q1 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements - Minichart
Cytek Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds - MSN
Earnings call transcript: Cytek Biosciences Q1 2026 sees revenue growth amid EPS miss - Investing.com
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Cytek Biosciences Inc. (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences Q1 Earnings Call Highlights - Barchart.com
Cytek Biosciences (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences, Inc. 1Q 2026: Revenue $44.14M, EPS ($0.15) — 10-Q Summary - TradingView
$44.1M quarter for Cytek Biosciences (NASDAQ: CTKB) as losses widen - Stock Titan
Cytek Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cytek Biosciences Q1 revenue rises 6%, slightly misses estimates - TradingView
Cytek adds 125 instruments as service revenue jumps 15% - Stock Titan
Wider loss as Cytek Biosciences (Nasdaq: CTKB) grows Q1 2026 sales - Stock Titan
Cytek Biosciences Reports First Quarter 2026 Financial Results - GlobeNewswire
Cytek Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday - MarketBeat
New Cytek Biosciences kit aims to boost high-resolution T cell analysis - Traders Union
Cytek Biosciences (NASDAQ: CTKB) details 2026 votes on board, pay and auditor - Stock Titan
[ARS] Cytek Biosciences, Inc. SEC Filing - Stock Titan
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):